Skip to main content
SpringerLink
Log in

Treatment of Metastatic Renal Cell Carcinoma

  • Chapter
Urologic Cancer: Chemotherapeutic Principles and Management

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 85))

Abstract

Renal cell carcinoma is the third most common urologic cancer. There are approximately 7,000 deaths annually due to this malignancy. In 1982, it is estimated that there will be 18,000 new cases identified. The disease is three times more common in males than females.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alberto P, Senn HJ (1974) Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs. Cancer 33: 1226–1229

    Article  PubMed  CAS  Google Scholar 

  2. Al-Sarraf M (1979) Abstract: The clinical trial of tamoxifen in patients with advanced renal cell cancer: a Southwest Oncology Group study. Proc AACR ASCO 20:378

    Google Scholar 

  3. Al-Sarraf M, Eyre H, Bonnet J, Saiki J, Gagliano R, Pugh R, Lehane D, Dixon D, Bottomley R (1981) Study of tamoxifen in metastatic renal cell carcinoma and the influence of certain prognostic factors: a southwest oncology group study. Cancer Treat Rep 65:447–451

    PubMed  CAS  Google Scholar 

  4. Anders CJ, Kemp NH (1961) Cyclophosphamide in treatment of disseminated malignant disease. Br Med J 2:1516–1523

    Article  PubMed  CAS  Google Scholar 

  5. Andrews NC, Wilson WL (1967) Phase II study of methotrexate (NSC-740) in solid tumors. Cancer Chemother Rep 51:471–474

    Google Scholar 

  6. Ansfield FJ, Schroeder JM, Curreri AR (1962) A preliminary comparison of 5-fluoro-2’deoxyuridine administered by rapid daily intravenous injections and by slow continuous infusion. Cancer Chemother Rep 16:289–390

    Google Scholar 

  7. Atkins HL, Gregg HG, Hyman GA (1962) Clinical appraisal of cyclophosphamide in malignant neoplasms. Cancer 15:1076–1080

    Article  PubMed  CAS  Google Scholar 

  8. Baumgartner G, Heinz R, Arbes H, Lenzhoffer R, Pridun N, Schuller J (1980) Methotrexate-citrovorum factor used alone and in combination chemotherapy for advanced hypernephromas. Cancer Treat Rep 64:41–46

    PubMed  CAS  Google Scholar 

  9. Baumgartner G, Heinz R, Linemayr G (1980) Methotrexate citrovorum factor therapy in advanced hypernephromas. (Germ) Wien Klin Wochenschr 92(15): 526–530

    CAS  Google Scholar 

  10. Bergman SM, Lippert M, Javadpour (1980) The value of whole lung tomography in the early detection of metastatic disease in patients with renal cell carcinoma and testicular tumors. J Urol 124:860–862

    PubMed  CAS  Google Scholar 

  11. Bergsagel DE, Levin WC (1960) A prelusive clinical trial of cyclophosphamide. Cancer Chemother Rep 8:120–134

    PubMed  CAS  Google Scholar 

  12. Bloom HJG, Wallace DM (1964) Hormones and the kidney: Possible therapeutic role of testosterone in a patient with regression of metastases from renal adenocarcinoma. Br Med J 2:476–480

    Article  PubMed  CAS  Google Scholar 

  13. Bloom HJG (1971) Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. Br J Cancer 25:250–265

    Article  PubMed  CAS  Google Scholar 

  14. Bloom HJG (1973) Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer 32:1066–1071

    Article  PubMed  CAS  Google Scholar 

  15. Boxer RJ, Waisman J, Lieber MM, Manpaso FM, Skinner DG (1979) Renal carcinoma: computer analysis of 96 patients treated by nephrectomy. J Urol 122:598–601

    PubMed  CAS  Google Scholar 

  16. Bukowski RM, LoBuglio A, McCracken J, Pugh R (1980) Phase II trial of Baker’s antifol in metastatic renal cell carcinoma: A Southwest Oncology Group Study. Cancer Treat Rep 64:1387–1388

    PubMed  CAS  Google Scholar 

  17. Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36:729–747

    Article  PubMed  CAS  Google Scholar 

  18. Choy DSJ, Arandia J, Rosenbaum I (1967) Clinical evaluation of a new alkylating agent, azetepa, in one hundred and twenty-five cases of malignant tumors. Int J Cancer 2:189–193

    Article  PubMed  CAS  Google Scholar 

  19. Concolino G, Marocchi A, Conti C, Tenaglia R, Silverio F, Brace U (1978) Human renal cell carcinoma as a hormone-dependent tumor. Cancer Res 38:4340–4344

    PubMed  CAS  Google Scholar 

  20. Costa G, Hreshchyshyn MM, Holland JF (1962) Initial clinical studies with vincristine. Cancer Chemother Rep 24:39–44

    PubMed  CAS  Google Scholar 

  21. Dana BW, Alberts DS (1981) Combination chemoimmunotherapy for advanced renal carcinoma with Adriamycin, bleomycin, vincristine, cyclophosphamide, plug BCG. Cancer Clin Trials 4:205–207

    PubMed  CAS  Google Scholar 

  22. Davis TE, Manalo FB (1978) Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine. Proc AACR ASCO 19:316

    Google Scholar 

  23. DeKernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma: computer analysis. J Urol 120:148–152

    PubMed  CAS  Google Scholar 

  24. DeKernion JB (1980) Lymphadenectomy for renal cell carcinoma: therapeutic implications. Urol Clin North Am 7: 697

    PubMed  CAS  Google Scholar 

  25. Dick DAL, Phillips AF (1961) Clinical experience with cyclophosphamide in malignant disease. Can Med Assoc J 85:947–986

    Google Scholar 

  26. Dorn III W, Gladden MP, Rankin EA (1975) Regression of a renal-cell metastatic osseous lesion following treatment. Bone Joint Surg 57A: 869–870

    Google Scholar 

  27. Fairlamb DJ (1981) Spontaneous regression of metastases of renal cancer: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 47:2102–2106

    Article  PubMed  CAS  Google Scholar 

  28. Falkson HC, Falkson G (1967) A clinical trial with hydroxyurea. Med Proc 13:436–438

    Google Scholar 

  29. Ferrazzi E, Salvagno L, Fornasiero A, Cartei G, Fiorentino M (1980) Tamoxifen treatment for advanced renal cell cancer. Tumori 66:601–605

    PubMed  CAS  Google Scholar 

  30. Feun LG, Drelichman A, Singhakowinte A, Vaitkevicius VK (1979) Letters: Phase II study of nafoxidine in the therapy for advanced renal carcinoma. Cancer Treat Rep 63:149–150

    PubMed  CAS  Google Scholar 

  31. Finney R (1973) An evaluation of postoperative radiotherapy in hypernephroma treatment — A clinical trial. Cancer 32:1332–1340

    Article  Google Scholar 

  32. Fossa SD, Talle K (1980) Treatment of metastatic renal cancer with ifosfamide and mesnum with or without irradiation. Cancer Treat Rep 64:1103–1108

    PubMed  CAS  Google Scholar 

  33. Fox MF (1965) The effect of cyclophosphamide on some urinary tract tumors. Br J Urol 37:399–409

    Article  PubMed  CAS  Google Scholar 

  34. Freed SZ, Halperin JP, Gordon M (1977) Idiopathic regression of metastases from renal cell carcinoma. J Urol 118:538–541

    PubMed  CAS  Google Scholar 

  35. Frei III E, Franzino A, Shnider BI, Costa G, Colsky J, Brindley CO, Hosley H, Holland JF, Gold GL, Jonsson U (1961) Clinical studies of vinblastine. Cancer Chemother Rep 12:125–129

    PubMed  Google Scholar 

  36. Frei III E, Bickers JN, Hewlett JS, Lane M, Leary WV, Talley RW (1969) Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res 29:1325–1332

    PubMed  CAS  Google Scholar 

  37. Garfield DH, Kennedy BJ (1972) Regression of metastatic renal cell carcinoma following nephrectomy. Cancer 30:190–196

    Article  PubMed  CAS  Google Scholar 

  38. Glick JH, Wein A, Torri S, Alavi J, Harris D, Brodovsky H (1980) Phase II study of tamoxifen in patients with advanced renal cell carcinoma. Cancer Treat Rep 64:343–344

    PubMed  CAS  Google Scholar 

  39. Gralla RJ, Yagoda A (1979) Phase II evaluation of chlorozotocin in patients with renal cell carcinoma. Cancer Treat Rep 63:1007–1008

    PubMed  CAS  Google Scholar 

  40. Hagan K, Trapp JD, Rhany RK, Reynolds VH (1974) Treatment of metastatic renal cell carcinoma. South Med J 67:1175–1178

    Article  PubMed  CAS  Google Scholar 

  41. Hahn DM, Schimpff S, Wiernik P, Sutherland J (1976) Single agent therapy for hypernephroma: CCNU, vinblastine, thiotepa & bleomycin. Proc AACR ASCO 17:82

    Google Scholar 

  42. Hahn DM, Schimpff SC (1977) Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thioTEPA, or bleomycin. Cancer Treat Rep 61:1585–1587

    PubMed  CAS  Google Scholar 

  43. Hahn RG, Brodovsky H (1976) Abstract: Methyl CCNU, velban and depo-provera treatment trials in advanced renal cancer. Proc AACR ASCO 17:246

    Google Scholar 

  44. Hahn RG, Temkin NR, Savlov ED, Perlia C, Wampler GL, Horton J, Marsh J, Carbone PP (1978) Phase II Study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep 62:1093–1095

    PubMed  CAS  Google Scholar 

  45. Hahn RG, Bauer M, Wolter J, Creech R, Bennett JM, Wampler GL (1979) Phase II Study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalaetitol in advanced renal cell cancer. Cancer Treat Rep 63:513–515

    PubMed  CAS  Google Scholar 

  46. Hahn RG, Begg CB, Davis T (1981) Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Cancer Treat Rep 65:711–713

    PubMed  CAS  Google Scholar 

  47. Haskell CM, Ossorio RC (1976) Abstract: Chemoimmunotherapy of metastatic breast cancer with Corynebacterium parvum (CP): A double blind randomized trial. Proc AACR ASCO 17:265

    Google Scholar 

  48. Hill JM, Loeb E (1961) Treatment of leukemia, lymphoma, and other malignant neoplasms with vinblastine. Cancer Chemother Rep 15:41–61

    PubMed  CAS  Google Scholar 

  49. Hindmarsh JR, Hall RR, Kulatilake AE (1979) Renal cell carcinoma: A preliminary clinical trial of methodichlorophen (D.D.M.P.). Clin Oncol 5:11–15

    PubMed  CAS  Google Scholar 

  50. Hire EA, Samson MK (1979) Use of VM-26 as a single agent in the treatment of renal carcinoma. Cancer Clin Trials 2:293–295

    PubMed  CAS  Google Scholar 

  51. Hogan TF, Citrin DL, Freeberg BL (1981) A preliminary report of mitotane therapy of advanced renal and prostate cancer. Cancer Treat Rep 65: 539–540

    PubMed  CAS  Google Scholar 

  52. Hogan TF (1979) Hormonal Therapy of Renal-Cell Carcinoma. In: Rose DP (ed) Endocrinology of Cancer. CRC, Boca Raton, pp 70–86

    Google Scholar 

  53. Horn Y, Hochman A (1967) The alkaloids of vinca rosea linn in malignant tumors. Oncology 21:214–220

    Article  PubMed  CAS  Google Scholar 

  54. Hrushesky WJ, Murphy GP (1977) Current status of the therapy of advanced renal carcinoma. J Surg Oncol 9:277–288

    Article  PubMed  CAS  Google Scholar 

  55. Hrushesky WJ (1977) Abstract: What’s old and new in advanced renal cell carcinoma. Proc AACR ASCO 18:318

    Google Scholar 

  56. Ishmael DR, Bottomley R, Geyer J (1980) Effect of nephrectomy on eventual response to chemotherapy in renal cell carcinoma. Proc AACR ASCO 21:429

    Google Scholar 

  57. Ishmael DR, Burpo LJ, Bottomley RH (1978) Abstract: Combined therapy of advanced hypernephroma with medroxyprogesterone, BCG, Adriamycin and vincristine. Proc AACR ASCO 19:407

    Google Scholar 

  58. Jenkin RDT (1967) Correspondence: Androgens in metastatic renal adenocarcinoma. Br Med J 11:361

    Article  Google Scholar 

  59. Johnson DE, Kaesler KE, Samuels ML (1975) Is nephrectomy justified in patients with metastatic renal cell carcinoma. J Urol 114:27

    PubMed  CAS  Google Scholar 

  60. Johnson DE, Rodriguez L, Holoye PY, Samuels ML (1975) Combination vincristine (NSC-67574) and hydroxyurea (NSC-32065) for metastatic renal carcinoma. Cancer Chemother Rep 59:1159–1160

    PubMed  CAS  Google Scholar 

  61. Johnson DE, Chalbaud RA, Holoye PY, Samuels ML (1975) Clinical trial of bleomycin (NSC-125066) in the treatment of metastatic renal carcinoma. Cancer Chemother Rep 59:433–435

    PubMed  CAS  Google Scholar 

  62. Juusela H, Malmio K, Alfthan O, Oravisto KJ (1977) Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 11:277

    Article  PubMed  CAS  Google Scholar 

  63. Katakkar SB, Franks CR (1978) Chemo-hormonal therapy for metastatic renal cell carcinoma with Adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate. Cancer Treat Rep 62:1379–1380

    PubMed  CAS  Google Scholar 

  64. Kato T, Nemoto R, Mori H, Kumagai I (1979) Correspondence: Microencapsulated mitomycin-C therapy in renal-cell carcinoma. Lancet 1:479–480

    Article  CAS  Google Scholar 

  65. Khung CL, Hall TC, Piro AJ, Dederick MM (1966) A clinical trial of oral 5-fluorouracil. Clin Pharmacol Ther 7:527–533

    PubMed  CAS  Google Scholar 

  66. Killien J, Hoth D, Smith F, Schein P, Woolley P, Lombardi VT (1980) Methyl-glyoxal-bis-quanylhydrazone (NSC 32946) (Methyl-G): Phase II experience and clinical pharmacology. Proc AACR ASCO 21: 368

    Google Scholar 

  67. Kiruluta G, Morales A, Lott S (1975) Response of renal adenocarcinoma to cyclophosphamide. Urology 6:557–558

    Article  PubMed  CAS  Google Scholar 

  68. Knight WA, Livingston RB, Fabian D, Costanzi J (1979) Phase I-II trial of methly-GAG: A southwest oncology group pilot study. Cancer Treat Rep 63:1933–1937

    PubMed  Google Scholar 

  69. Knight WA, Livingston RB, Fabian C, Costanzi J (1980) Methylglyoxal-bis-guanylhy- drazone (methyl GAG, MGBG) in advanced renal carcinoma. Proc AACR ASCO 21:367

    Google Scholar 

  70. Knost JA, Oldham RK, Hande KR, Rhamy RK, Greco FA (1981) Combination of vinblastine and bleomycin in metastatic renal cell carcinoma. Cancer Treat Rep 65:349–350

    PubMed  CAS  Google Scholar 

  71. Kofman S, Eisenstein R (1963) Mithramycin in the treatment of disseminated cancer. Cancer Chemother Rep 32:77–96

    PubMed  CAS  Google Scholar 

  72. Legha S, Muggia FM (1976) Antiestrogens in the treatment of cancer (correspondence). Ann Intern Med 84: 751

    PubMed  CAS  Google Scholar 

  73. Lemon HM, Miller DM, Smith J, Walker EE (1964) Remission of metastases of erythropoietin-secreting renal cell adenocarcinoma after 6-mercaptopurine (NSC-755) therapy. Cancer Chemother Rep 36:49–140

    PubMed  CAS  Google Scholar 

  74. Lerner H, Beckloff GL (1965) Hydroxyurea administered intermittently JAMA 192:138–140

    Google Scholar 

  75. Levi JA, Dalley D, Aroney R (1980) Abstract: A comparative trial of the combination vinblastine (V), methotrexate (A) and bleomycin (B) with and without tamoxifen (T) for metastatic renal cell carcinoma (RCC). Proc AACR ASCO 21:426

    Google Scholar 

  76. Lokich JJ, Harrison JH (1975) Renal cell carcinoma: Natural history and chemothera- peutic experience. J Urol 114:371–374

    PubMed  CAS  Google Scholar 

  77. Love DR (1979) Computed tomograph staging of renal carcinoma. Urol Radiol 1:3

    Article  PubMed  CAS  Google Scholar 

  78. Luce JK, Thurman WG, Issacs BL, Talley RW (1970) Clinical trials with the antitumor agent 5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide (NSC-45388). Cancer Chemother Rep 54:119–124

    PubMed  CAS  Google Scholar 

  79. MacErlean DP, Owena AP, Bryan PJ (1980) Hypernephroma embolisation — is it worthwhile? Clin Radiol 31:297–300

    Article  PubMed  CAS  Google Scholar 

  80. Maskens AP, Hap B, Kozyreff VN, Callewaert W, Lion G, Van den Abbeele KG (1980) Abstract: Serum levels of medroxyprogesterone acetate under various treatment schedules. Proc AACR ASCO 21:165

    Google Scholar 

  81. McNichols DW, Segura JW, Wu S, Safire GE (1981) Renal cell carcinoma: Long-term survival and late recurrence. J Urol 126:17–23

    PubMed  CAS  Google Scholar 

  82. Melander O, Notter G, Schreeb T von (1967) Hormone treatment of metastasizing renal cancer. Nord Med 78:1309

    Google Scholar 

  83. Merrin C, Mittleman A, Fanous N, Wajsman Z, Murphy GP (1975) Chemotherapy of advanced renal cell carcinoma with vinblastine and CCNU. J Urol 113:21–23

    PubMed  CAS  Google Scholar 

  84. Miller CF, Blom J, Tripler AMC, Reed N (1980) Abstract: Adjuvant chemotherapy of renal cell carcinoma using a combination of bleomycin (BLM) and lomustine (CCNU). Proc AACR ASCO 21: 362

    Google Scholar 

  85. Mittelman A, Albert DJ, Murphy GP (1973) Lomustine treatment of metastatic renal cell carcinoma. JAMA 225:32–35

    Article  PubMed  CAS  Google Scholar 

  86. Montie JE, Stewart BH, Straffon RA, Banowsky LHW, Hewitt CB, Montague DK (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117:272–275

    PubMed  CAS  Google Scholar 

  87. Moore GE, Brass DJ, Ausman R, Nadler S, Jones R, Slack N, Rimm AA (1968) Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer. Cancer Chemother Rep 52:661–666

    PubMed  CAS  Google Scholar 

  88. Moore GE, Brass DJ, Audman R, Nadler S, Jones R, Slack N, Rimm AA (1968) Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Cancer Chemother Rep 52:641–653

    PubMed  CAS  Google Scholar 

  89. Morales A, Kiruluta G, Lott S (1975) Hormones in the treatment of metastatic renal cancer. J Urol 114:692–693

    PubMed  CAS  Google Scholar 

  90. Morales A, Wilson JL, Pater JL, Loeb M (1982) Cyto-reductive surgery and systemic bacillus Calmette-guerin therapy in metastatic renal cancer: A phase II trial. J Urol 127:230–235

    PubMed  CAS  Google Scholar 

  91. Mulder JH, Alexieva-Figusch I (1979) Abstract: Tamoxifen in metastatic renal cell carcinoma (meeting abstract). Cancer Treat Rep 63(7): 1222

    Google Scholar 

  92. Murphy GP (1978) Chemotherapy of renal, bladder, and prostate cancer. In: Brodsky I, Kahn SB, Conroy J (eds) Cancer chemotherapy III. Grune & Stratton, New York, pp 179–194

    Google Scholar 

  93. Nevinny HB, Hall TC (1968) Chemotherapy with hydroxyurea (NSC-32065) in renal cell carcinoma. J Clin Pharmacol 8:352–359

    CAS  Google Scholar 

  94. O’Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G (1973) Phase II evaluation of Adriamycin in human neoplasia. Cancer 32:1–8

    Article  PubMed  Google Scholar 

  95. O’Dea MJ, Zincke H, Utz DC, Bernatz PE (1978) The treatment of renal cell carcinoma with solitary metastasis. J Urol 120:540–542

    PubMed  Google Scholar 

  96. Paine CH, Wright FW, Ellis F (1970) The use of progestogen in the treatment of metastatic carcinoma of the kidney and uterine body. Br J Cancer 24:277–282

    Article  PubMed  CAS  Google Scholar 

  97. Paladine W, Longacre D, Hemmings P, Harper G (1979) Nafoxidine, an antiestrogen in hypernephroma (ASCO abs). Proc AACR ASCO 20:293

    Google Scholar 

  98. Papac R, Luikhart S, Kirkwood J (1980) Abstract: High dose tamoxifen in patients with advanced renal cell cancer and malignant melanoma. Proc AACR ASCO 20:358

    Google Scholar 

  99. Papac RJ, Ross SA, Levy A (1977) Renal cell carcinoma: Analysis of 31 cases with assessment of endocrine therapy. Am J Med Sci 274: 281–290

    Article  PubMed  CAS  Google Scholar 

  100. Pasmantier MW, Coleman M, Kennedy BJ, Eagan R, Carolla R, Weiss R, Leone L, Silver RT (1977) Piperazinedione in metastatic renal papac carcinoma. Cancer Treat Rep 61:1731–1732

    PubMed  CAS  Google Scholar 

  101. Patel NP, Lavengood RW (1978) Renal cell carcinoma: Natural history and results of treatment. J Urol 119:722–726

    PubMed  CAS  Google Scholar 

  102. Peterson LJ, Grimes JH, Dees JE, Anderson EE (1974) Hormonal therapy in metastatic hypernephroma. Urology 4:669–673

    Article  PubMed  CAS  Google Scholar 

  103. Ramirez G, Weiss AJ, Rochlin DB, Bisel HF (1971) Phase II study of 6-methylpregn-r-ene-3,11,20-trione (NSC-17256). Cancer Chemother Rep 55:265–268

    PubMed  CAS  Google Scholar 

  104. Regelson W, Holland JF, Gold GL, Lynch J, Olson KB, Horton J, Hall TC, Krant M, Colsky J, Miller SP, Owens A (1967) 6-mercaptopurine (NSC-755) given intravenously at weekly intervals to patients with advanced cancer. Cancer Chemother Rep 51: 277–282

    Google Scholar 

  105. Richards II Frederick, Muss HB, White DR, Cooper MR, Spurr CL (1977) CCNU, bleomycin, and methylprednisolone with or without Adriamycin in renal cell carcinoma: A randomized trial. Cancer Treat Rep 61:1591–1593

    PubMed  Google Scholar 

  106. Richie JP, Wand BS, Steele GD, Wilson RE, Mannick JA (1980) In vivo and in vitro effects of xenogeneic immune ribonucleic acid in patients with advanced renal cell carcinoma: A phase I study. J Urol 126:24–28

    Google Scholar 

  107. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297–301

    PubMed  CAS  Google Scholar 

  108. Rochlin DB, Shiner J, Langdon E, Ottoman R (1962) Use of 5-fluorouracil in disseminated solid neoplasms. Ann Surg 156:105–113

    Article  PubMed  CAS  Google Scholar 

  109. Rodriguez LH, Johnson DE (1978) Clinical trial of cis-platinum (NSC 119875) in metastatic renal cell carcinoma. Urology 11:344–346

    Article  PubMed  CAS  Google Scholar 

  110. Sadoff L, Lusk W (1974) The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of Cortisol T4 LH and testosterone in patients with advanced cancer. Obstet Gynecol 43:262–267

    PubMed  CAS  Google Scholar 

  111. Salimtschik M, Mouridsen HT, Loeber J, Johansson E (1980) Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes. Cancer Chemother Pharmacol 4:267–269

    Article  PubMed  CAS  Google Scholar 

  112. Samson MK, Baker LH, Devos JM, Burker TR, Izbicki RM, Vaitkevicius VK (1976) Phase I clinical trial of combined therapy with vinblastine (NSC-49842), bleomycin (NSC-125066), and cis-dichlorodiammineplatinum(II) (NSC-119875). Cancer Treat Rep 60:91–97

    PubMed  CAS  Google Scholar 

  113. Samuels ML, Sullivan P, Howe GD (1968) Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma). Cancer 22:525–532

    Article  PubMed  CAS  Google Scholar 

  114. Schneider RJ, Woodcock TM, Yagoda A (1980) Phase II trial of 4’-(9-aeridinylami no)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma. Cancer Treat Rep 64:183–185

    PubMed  CAS  Google Scholar 

  115. Schumacher HR, O’Connell JP (1963) The intravenous use of uracil mustard (U-8344). Cancer 16:345–349r

    Article  PubMed  CAS  Google Scholar 

  116. Shnider BI, Gold GL, Hall T, Dederick M, Nevinny HB, Patee KG, Lasagna L, Owens AH, Hreschyshyn M, Selawry O, Holland JF, Franzino A, Zubrod CG, Frei E, Brindley C (1960) Preliminary studies with cyclophosphamide. Cancer Chemother Rep 8:106–111

    PubMed  CAS  Google Scholar 

  117. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971) Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28:1165–1177

    Article  PubMed  CAS  Google Scholar 

  118. Skinner DG, DeKernion JG (eds) (1978) Genitourinary Cancer, Saunders, Philadelphia, pp 128–129

    Google Scholar 

  119. Smart CR, Rochlin DB, Nahum AM, Silva A, Wagner D (1964) Clinical experience with vinblastine sulfate (NSC-49842) in squamous cell carcinoma and other malignancies. Cancer Chemother Rep 34:31–45

    PubMed  CAS  Google Scholar 

  120. Solomon J, Alexander MJ, Steinfeld J (1963) Cyclophosphamide: a clinical study. JAMA 183:165–170

    PubMed  CAS  Google Scholar 

  121. Stolbach LL, Begg CB, Hall T, Horton J (1981) Treatment of renal carcinoma: A phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine. Cancer Treat Rep 65: 689–692

    PubMed  CAS  Google Scholar 

  122. Swanson DA, Johnson DE (1980) A clinical trial of estramustine phosphate (NSC 89199) in the management of metastatic renal cell carcinoma (meeting abstract). Proc AACR ASCO 21:346

    Google Scholar 

  123. Swanson DA, Johnson DE (1981) Estramustine phosphate (EMCYT) as treatment for metastatic renal carcinoma. Urology 17:344–346

    Article  PubMed  CAS  Google Scholar 

  124. Swanson DA, Wallace S, Johnson DE (1980) The role of embolization and nephrectomy in the treatment of metastatic renal carcinoma. Urol Clin North Am 7:719–730

    PubMed  CAS  Google Scholar 

  125. Talley RW (1973) Chemotherapy of the adenocarcinoma of the kidney. Cancer 32:1062–1065

    Article  PubMed  CAS  Google Scholar 

  126. Talley RW, Moorhead EL, Tucker WG, SanDiego EL, Brennan MJ (1969) Treatment of metastatic hypernephroma. JAMA 207:322–328

    Article  PubMed  CAS  Google Scholar 

  127. Talley RW, Oberhauser NA, Brownlee RW, O’Bryan RM (1979) Chemotherapy of metastatic renal adenocarcinoma with a five-drug regimen. Henry Ford Hosp Med J 27:110–112

    Google Scholar 

  128. Tisman G, Kellon DB, Wu S, Safire GE (1976) Use of tamoxifen in tumors other than breast cancer. Clin Res 24: 381A

    Google Scholar 

  129. Todd III RF, Garnick MB, Canellos GP (1980) Abstract: Chemotherapy of advanced renal adenocarcinoma with methyl-glyoxal-BIS-guanylhydrazone (methyl-GAG). Proc AACR ASCO 21:340

    Google Scholar 

  130. Todd FR, Garnick MB, Canellos GP, Richie JP, Gittes RF, Mayer RJ, Skarin AT (1981) Phase I-II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma. Cancer Treat Rep 65:17–20

    PubMed  Google Scholar 

  131. Tolia BM, Whitmore WF Jr (1975) Solitary metastasis from renal cell carcinoma. J Urol 114:836–837

    PubMed  CAS  Google Scholar 

  132. Van Echo DA, Markus S, Aisner J, Wiernik PH (1980) Phase II trial of 4’-(9-acri- dinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma. Cancer Treat Rep 64:1009–1010

    PubMed  Google Scholar 

  133. Vosika GJ, Ryan MJ, Fortuny IA, Meyer C, Kiang DT, Theologides A, Kennedy BJ (1978) CCNU vinblastine and delalutin therapy in renal cell carcinoma. Med Pediatr Oncol 5:89–91

    Article  PubMed  CAS  Google Scholar 

  134. Wagle DG, Murphy GP (1971) Hormonal therapy in advanced renal cell carcinoma. Cancer 28:318–321

    Article  PubMed  CAS  Google Scholar 

  135. Wajsman Z, Beckley S, Madajewicz S, Dragone N (1980) Abstract: high dose cyclophosphamide (CPM) in metastatic renal cell cancer. Proc AACR ASCO 21:423

    Google Scholar 

  136. Watne AL, Badillo J, Koike A, Kondo T, Moore GE (1960) Clinical studies of actinomycin D. Ann NY Acad Sci 89:445–453

    Article  PubMed  CAS  Google Scholar 

  137. Watne AL, Moore D, Gorgun B (1967) Solid tumor chemotherapy with mitomycin C. Arch Surg 95:175–178

    Article  PubMed  CAS  Google Scholar 

  138. Weiselberg L, Budman D, Vinciguerra V, Sehulman P, Degnan TJ (1981) Tamoxifen in unresectable hypernephroma: A phase II trial and review of the literature. Cancer Clin Trials 4:195–198

    PubMed  CAS  Google Scholar 

  139. Weiss AJ, Jackson LG, Carabasi R (1961) An evaluation of 5-fluorouracil in malignant disease. Ann Intern Med 55:731–741

    PubMed  CAS  Google Scholar 

  140. Werf-Messing B Van der (1973) Carcinoma of the kidney. Cancer 32:1056–1066

    Article  PubMed  Google Scholar 

  141. Werf-Messing B Van der, Mulder J (1974) Metastatic kidney cancer treated with multiple drug therapy at the Rotterdam Radiotherapy Institute. Br J Cancer 29:491–492

    Article  PubMed  Google Scholar 

  142. Werf-Messing B Van der, Van Gilse HA (1971) Hormonal treatment of metastases of renal carcinoma. Br J Cancer 25:423–427

    Article  PubMed  Google Scholar 

  143. White JE, Ricketts WN, Strudwick WJ (1962) A clinical study of 5-fluorouracil in a variety of far advanced human malignancies. J Natl Med Assoc 54:315

    PubMed  CAS  Google Scholar 

  144. Wilson WL, Bisel HF, Krementa ET, Lein RC, Prohaska JV (1967) Further clinical evaluation of 2’-deoxy-5-fluorouridine (NSC-27640). Cancer Chemother Rep 51:85–90

    PubMed  CAS  Google Scholar 

  145. Wong PP, Yagoda A, Currie VE, Young CA (1977) Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma. Cancer Treat Rep 61:1727–1729

    PubMed  CAS  Google Scholar 

  146. Woodruff MW, Wagle D, Gailani SD, Jones R (1967) The current status of chemotherapy for advanced renal carcinoma. J Urol 97:611–618

    PubMed  CAS  Google Scholar 

  147. Wright TL, Hurley J, Korst DR, Monto RW, Röhn RJ, Will JJ, Louis J (1963) Vinblastine in neoplastic disease. Cancer Res 23:169–179

    Google Scholar 

  148. Zeffren J, Yagoda A, Watson RC, Natale RB, Blumenreich MS, Chapman R, Howard J (1981) Phase II trial of methyl-GAG in advanced renal cancer. Cancer Treat Rep 65: 525–527

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Stanford University Medical Center, Palo Alto, CA, USA

    F. M. Torti

Authors
  1. F. M. Torti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Medical Oncology Stanford University Medical Center, Palo Alto Veterans Administration Medical Center and the Northern California Cancer Program, Palo Alto, CA, USA

    Frank M. Torti MD

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Torti, F.M. (1983). Treatment of Metastatic Renal Cell Carcinoma. In: Torti, F.M. (eds) Urologic Cancer: Chemotherapeutic Principles and Management. Recent Results in Cancer Research, vol 85. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81994-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81994-0_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81996-4

  • Online ISBN: 978-3-642-81994-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation